Ceptaris Therapeutics (Malvern, PA) a clinical-stage specialty pharmaceutical company focused on the treatment of mycosis fungoides, a type of cutaneous t-cell lymphoma, closed a $14.4M Series D financing. Participants include Vivo Ventures, Palo Alto Investors, Burrill & Co. and Aperture Venture Partners.
Thanx for your patience as we catch-up.

ProtonMedia (Landsdale, PA) a commercial-stage cloud-based life science product lifecycle project management platform, closed a $4.5M Series B financing. Participants include Kaplan Ventures.
The 2Q11 OnBioVC Trend Analysis will be published on Tue 6 September. Advertising opportunities are still available. Reach >45,000 high-value targeted life science professionals on-line and in-print. Contact arubenstein@rnaventures.com for details.

Neuronetics (Malvern, PA) a commercial-stage medical device company focused on pulsed magnetic field stimulation for non-invasive, non-systemic treatment of depression, closed a $30M Series E financing. Participants include Polaris Venture Partners, Pfizer Venture Investments, Investor Growth Capital, New Leaf Venture Partners, Interwest Partners, Three Arch Partners, Quaker BioVentures and Onset Ventures.

TetraLogic Pharmaceuticals (Malvern, PA) a clinical-stage pharmaceutical company developing novel small molecule drugs to treat cancer, closed a $6M Series C financing bringing the total round to $43M. Participants include Nextech Invest, Clarus Ventures, Hatteras Venture Partners, Pfizer Venture Investments, HealthCare Ventures, Latterell Venture Partners, Novitas Capital, Quaker BioVentures, Vertical Group and Amgen Ventures.

Carmell Therapeutics (Pittsburgh, PA) a development-stage biopharmaceutical company focused on biomaterials for connective tissue repair, closed a $2.4M Series A financing. Participants include Harbor Light Capital Partners, Newlin Investment Company, PLSG Accelerator Fund, Innovation Works, Ariel Savannah Angels and Blue Tree Allied Angels.

TetraLogic Pharmaceuticals (Malvern, PA) a clinical-stage biopharmaceutical company developing novel small molecule drugs to treat cancer, closed a $23M Series C financing. Participants include Clarus Ventures, Hatteras Venture Partners, Pfizer Venture Investments, HealthCare Ventures, Latterell Venture Partners, Novitas Capital, Quaker BioVentures, The Vertical Group and Amgen Ventures.

Core Essence Orthopaedics (Fort Washington, PA) a commercial-stage medical device company focused on MIS arthroscopic and endoscopic procedures involving soft tissue and skeletal repair, closed a $11.5M Series B financing. Participants include Baird Venture Partners, NewSpring Health Capital and Robin Hood Ventures.

BioNanomatrix (Philadelphia, PA) commercial-stage developer of a nanochannel array chip, single-molecule imaging and analysis platform, closed a $23.3M Series B financing. Participants include Domain Associates, Gund Investment Corp., Battelle Ventures, Innovation Valley Partners and KT Venture Group.

NeoGraft Technologies (Pittsburgh, PA) a development-stage medical device company focused on coronary artery disease, closed a $3M Series B financing. Participants were not identified.

Small Bone Innovations (Morrisville, PA) a commercial-stage a small bone and joint device company focused on arthroplasty, fixation, trauma and biologic solutions, closed a $15M Series F financing. Participants have included 3i Group, NGN Capital, Trevi Health Ventures, Viscogliosi Brothers, Vollin Holdings and The Family Office Co.

ClearCount Medical Solutions (Pittsburgh, PA) a commercial-stage company focused on patient safety with RFID tagged surgical smart sponges for surgical reconciliation and operational efficiency, closed a $5M Series B financing. Participants include Draper Triangle Ventures and Draper Fisher Jurvetson.

TetraLogic Pharmaceuticals (Malvern, PA) a clinical-stage small molecule company focused on apoptosis and necrosis modulation for potential cancer, cardiovascular, neurological and ophthalmic disease treatment, closed a $5M Series C financing, bringing the total round to $37M. Participants include Pfizer Venture Investments, Clarus Ventures, Hatteras Venture Partners, Amgen Ventures, HealthCare Ventures, Latterell Venture Partners, Novitas Capital, [...]

Gemin X Pharmaceuticals (Malvern, PA) a clinical-stage biopharmaceutical company focused on chronic lymphocytic leukemia, melanoma, small cell lung cancer, lymphoma, myeloma and glioblastoma multiforme, closed a $8M Series E financing. Participants include Caxton Advantage Life Sciences Fund and Sanderling Ventures.